Last synced from Twitter 17m ago
Susan Desmond-Hellmann Elected to Pfizer’s Board of Directors
Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Desmond-Hellmann to its Board of Directors, effective immediately. Dr. Desmond-Hellmann, age 62, was also appointed to the Governance Sustainability Committee and the Science and...
I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China
- The clinical study will evaluate the safety and preliminary efficacy of TJC4, in patients with relapsed or refractory acute myeloid leukemia (AML) and...
Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA
NEW YORK , April 01, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic...
Brad Loncar
Here's some good news for a change...check out the chairman's quote in the press release. His daughter had neuroblastoma so he started a company for it. Just filed their BLA today. ir.ymabs.com/news-releases/… pic.twitter.com/GCVTRhs4dm
15h
MassBio Forums - Massachusetts Biotechnology Council
Attend our targeted professional development and networking events uniquely designed for every type of life sciences professional.
With record-setting speed, vaccine makers take their first shots at the new coronavirus
Two candidate vaccines start trials while dozens more are rushed into development
1
Brad Loncar
This is a good overview of the strategies behind some of the vaccines that are in development.
34h
Hong Kong-listed healthcare stocks outperform amid coronavirus uncertainty
That market trend could continue in the short term, according to some experts, although some healthcare segments such as generic drug suppliers also face production disruptions arising from the pandemic.
A Spur to the Biotech Century Ahead
The effort to defeat the coronavirus will focus the attention of a new generation of scientific pioneers.
How to create live videos on Twitter
Learn how to find and create your own live videos on Twitter, and be a part of what's happening live in the world.
Agios Provides Update on 2016 Collaboration Agreement with Celgene, a Wholly Owned Subsidiary of Bristol Myers Squibb
The Investor Relations website contains information about Agios Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
ETF Prime Podcast: Companies Targeting The Virus
Also a look at ETF flows and the Federal Reserve announcement to buy corporate bond ETFs.
Biotech stocks are down, but optimistic investors see opportunities ahead
In this edition: the opportunity for convalescent plasma; shameless fund-raising stunts; and a biotech buyside investor survey.
Collaboration with AstraZeneca - RNS - London Stock Exchange
Collaboration with AstraZeneca RNS - regulatory news service - news
AstraZeneca to discover and develop siRNA therapeutics for Cardiovascular, Renal, Metabolic and Respiratory diseases in new collaboration
Brad Loncar
Astra is partnering with Silence Therapeutics on siRNA programs. I don’t see any financial details.
8d
Biotech Expert Brad Loncar Goes In-Depth on Coronavirus Treatments & Vaccines
Biotech expert Brad Loncar explains why COVID-19 should be taken seriously and goes in-depth on the companies rapidly developing treatments and vaccines. ETF.com’s Drew Voros highlights ETF flows and discusses the Fed’s decision to purchase...
CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer
- Collaboration to Utilize CytomX’s Novel Probody ® Technology Platform for CD3 Bispecific Targets - - CytomX to Receive $80 Million Upfront Payment and Ability to Exercise Option for U.S. Co-Commercialization Rights - SOUTH SAN...
Brad Loncar
Remember non-coronavirus news? $80M up front to CytomX in a collaboration with Astellas for probody bispecifics.
10d
Gilead Sciences' (GILD) Remdesivir Granted FDA Orphan Drug Status for Treatment of COVID-19
Gilead Sciences' (NASDAQ: GILD) Remdesivir Granted FDA Orphan Drug Status for Treatment of coronavirus disease 2019 (COVID-19...